Increased glucose consumption is a hallmark of cancer cells. The increased consumption and subsequent metabolism of glucose during proliferation creates the need for a constant supply of NAD, a co-factor in glycolysis. Regeneration of the NAD required to support enhanced glycolysis has been attributed to the terminal glycolytic enzyme, lactate dehydrogenase (LDH). However, loss of glucose carbons to biosynthetic pathways early in glycolysis reduces the carbon supply to LDH. Thus, alternative routes for NAD regeneration must exist to support the increased glycolytic rate while allowing for the diversion of glucose to generate biomass and support proliferation. Here we demonstrate, using a variety of cancer cell lines as well as activated primary T cells, that cytosolic malate dehydrogenase 1 (MDH1) is an alternative to LDH as a supplier of NAD. Moreover, our results indicate that MDH1 generates malate with carbons derived from glutamine, thus enabling utilization of glucose carbons for glycolysis and for biomass. Amplification of MDH1 occurs at an impressive frequency in human tumors and correlates with poor prognosis. Together, our findings suggest that proliferating cells rely on both MDH1 and LDH to replenish cytosolic NAD, and that therapies designed at targeting glycolysis must consider both dehydrogenases.
INTRODUCTION
Cancer cells rewire their metabolism in a variety of ways to support de novo synthesis of macromolecules needed for proliferation. They increase their consumption of glucose, but uncouple glycolysis from the citric acid cycle (TCA), diverting glucose carbon into biosynthetic pathways that support growth and proliferation. 1 A constant supply of cytosolic NAD, which serves as an electron acceptor in the reaction catalyzed by glyceraldehyde-3-phosphate dehydrogenase (GAPDH), is required to sustain the enhanced glycolysis associated with proliferation. The cytosolic pool of NAD/NADH is independent of the mitochondrial NAD/NADH pool involved in the electron transport chain. The regeneration of cytosolic NAD from NADH has been largely attributed to the production of lactate from pyruvate by the lactate dehydrogenase (LDH) enzyme. 1, 2 However, given that diversion of glucose carbons for biomass reduces the flow of carbons to pyruvate, it is evident that LDH activity alone cannot satisfy the increased need for cytosolic NAD in these cells. 3 Under these circumstances, how do cancer cells resupply GAPDH with its co-factor NAD at a rate conducive to maintaining the accelerated glycolysis required for proliferation?
In this study, we set out to identify alternative reactions that could support the sustained glycolytic rate exhibited by proliferating cells. We report the generation of malate through malate dehydrogenase 1 (MDH1) supports LDH to regenerate NAD during proliferation. MDH1 deletion in cancer cells slowed proliferation and glucose consumption. In human tumors, MDH1 amplification is a prominent genomic aberration and correlates with poor prognosis. Furthermore, we demonstrate that reductive metabolism of glutamine provides carbon for the MDH1 reaction. Overall, our results suggest MDH1 works with lactate dehydrogenase A (LDHA) during Warburg metabolism in proliferating cells and that therapies targeting glycolysis in cancer cells must consider targeting MDH1.
RESULTS

MDH activity helps regenerate cytosolic NAD in proliferating cells
We previously demonstrated that stable overexpression of the Bcl-2 family member Noxa increased glucose consumption, extracellular acidification and promoted greater dependence on the pentose phosphate pathway in Jurkat leukemia cells. At the same time, the Noxa-overexpressing (N5) cells showed lower glycolysis completion rates, suggesting reduced flux of glucose carbons to lactate. 4 We used this isogenic model to trace the flow of deuterium from the glucose isotopomer, [4- 2 H]-glucose, to cytosolic NADH, and hence to metabolites generated from NADH-dependent dehydrogenase activity ( Figure 1a ). We assayed M1-enriched metabolites by gas chromatography-coupled mass spectrometry (GC-MS) following 24 h of labeling with [4- 2 H] glucose. As expected, the highest concentration of M1-labeled metabolite was lactate (Supplementary Figure 1a) . However, we detected increased M1 enrichment of additional metabolites in N5 cells, suggesting that other dehydrogenase(s) in addition to LDH were involved in regenerating cytosolic NAD during Warburg metabolism (Figure 1b; Supplementary Figure 1a) . Although lactate production and accumulation are well documented in cancer cells (reviewed in Hirschhaeuser et al. 5 ), most other M1-labeled metabolites we detected are substrates for other reactions, which made direct comparison of the concentration (peak area) of M1 metabolites difficult. Instead, we focused on the M1 enrichment levels of the individual metabolites in N5 cells as a consequence of increased glycolysis (Figure 1b) . The M1 malate pool showed the highest increase in N5 cells over parental cells, followed by aspartate and fumarate. Fumarate is likely to be an additional indicator of malate enrichment, given that it is not directly associated with a dehydrogenase and can be generated from malate via cytosolic fumarase. M1-labeled aspartate is also likely to be derived from fumarate which, as a symmetrical molecule could retain the M1 hydrogen label as it returns to malate through fumarase and then OAA on its way to aspartate synthesis by aspartate transaminase. An alternative explanation for M1-labeled aspartate is aspartate dehydrogenase, which generates aspartate from OAA using NADH and free ammonia, has been reported in humans based on homology. 6 However, nuclear magnetic resonance analysis indicated that the deuterium from NADH was associated with the β-carbon of aspartate (Supplementary Figure 1b) and not the α-carbon predicted from the aspartate dehydrogenase activity reported in other species. 7 These findings suggest that the increased M1-labeled aspartate and fumarate we observe in N5 cells originate from malate. Thus, we focused on the cytosolic MDH1 enzyme, a component of the malate aspartate shuttle, which moves electrons in the form of NADH from the cytosol into the mitochondria through malate (reviewed by Menzies et al. 8 ). Although MDH1 is recognized as a source of NAD in differentiated cells, its role in proliferation and cancer has not been described.
To further investigate the involvement of malate in the regeneration of cytosolic NAD in proliferating cells, primary human T cells were stimulated to proliferate using anti-CD3/anti-CD28-based receptor co-stimulation. Upon activation, primary T cells switch to a glycolytic phenotype and increase their glucose consumption. 9, 10 We assessed the transfer of deuterium from H] glucose to malate and lactate in primary CD3+ T cells purified from normal human donor peripheral blood mononuclear cells (PBMCs) following 24 h of stimulation. Consistent with published studies, levels of M1-labeled lactate increased following stimulation (Figure 1c) . However, the enrichment of M1 malate also increased, demonstrating that malate synthesis through MDH1 is a significant route for regenerating cytosolic NAD in activated T cells (Figure 1c ). To better understand the contribution of malate synthesis to the regeneration of cytosolic NAD, we examined malate and lactate flux in HeLa cells, commonly used as models for Warburg metabolism for their highly glycolytic phenotype. [11] [12] [13] Intracellular M1 enrichment of malate occurred rapidly, reaching steady state at 6 h after labeling with [4- 2 H] glucose ( Figure 1d ). MDH1 activity kinetics mirror that of LDHA further demonstrating a relationship between MDH1 activity and glucose consumption, and suggesting, moreover, that OAA, the substrate for the MDH1 reaction, is readily available in the cytosol. The results in Figure 1 demonstrate the contribution of malate to glycolysis in both non-adherent and adherent cancer cell lines. Interestingly, M1 malate also increased over time in the medium (Supplementary Figure 1c) , suggesting that malate that accumulates in the cytosol during proliferation is in excess of amounts the malate aspartate shuttle is able to process. Overall, these data point to a significant role for MDH in replenishing the cytosolic NAD required to support glycolysis in proliferating cells.
MDH1 supports proliferation and glucose consumption in cancer cells To evaluate the contribution of MDH1 to the proliferative state, we utilized Jurkat cells knocked out for MDH1 14 ( Figure 2a ). Figure 2b shows that MDH1 knockout (KO) cells proliferate at a significantly lower rate. They also consume less glucose per cell than their wildtype counterparts (Figure 2c ). MDH1 support of glycolysis would predict that less pyruvate is available for NAD regeneration via LDHA in the KO cells, and that addition of exogenous pyruvate should allow MDH1 KO cells to increase their proliferation rate. Indeed, MDH1 KO cells were rescued by pyruvate (Figure 2d ). However, glucose consumption by these cells was not affected by pyruvate addition (data not shown). These results are consistent with recent studies that suggest the cellular NAD/NADH ratio must be maintained to sustain proliferation and may serve a purpose in addition to that of supplying GAPDH and glycolysis. 15, 16 We also surmised that cells lacking MDH1 should exhibit greater dependence on LDHA to sustain glycolysis. Consistent with our hypothesis, the basal extracellular acidification rate of the MDH1 KO cells was significantly higher than that of wild type (Figure 3a ).
LDHA inhibition has been shown to be effective at inhibiting aerobic glycolysis in several cancer cell types and is under consideration as a clinical therapeutic. [17] [18] [19] [20] We hypothesized that LDHA inhibitors would be less effective at suppressing proliferation in cells that utilize MDH1 for NAD regeneration than in cells that lacked the enzyme. We used the LDHA inhibitor (LDHAi) GSK2837808A 17, 20 to inhibit lactate production in the MDH1 KO cell model (Figure 3b ). LDH inhibition had no effect on the growth of MDH1 wild-type cells, but significantly suppressed proliferation of MDH1 KO cells without inducing apoptosis ( 
MDH1 is amplified in human tumors
If MDH1 activity is critical for supporting proliferative metabolism, overexpression of the wild-type enzyme should impart a growth advantage and be selected for in cancers and specifically in tumors that arise in nutrient limited environments. The Cancer Genome Atlas database and cBioPortal 21, 22 showed MDH1 to be mutated in o1% of tumor samples queried (Supplementary Figure 4a) . Moreover, amplification of this enzyme was preferred to deletion across tumor types (Figure 4a ). MDH1 was amplified in almost 11% of one squamous cell lung carcinoma data set, and a second MDH1-amplified squamous cell lung carcinoma subset showed~50% reduction in disease-free survival rate (Figure 4b ). Notably, MDH1 was more frequently amplified than LDHA in the The Cancer Genome Atlas database, and the amplifications were almost always mutually exclusive (Figure 4c ; Supplementary  Figure 3b) , which suggests a level of redundancy among these dehydrogenases and highlights the need to target both. Notably, the genomic locus of MDH1 (2p13) is not a commonly reported amplification event, suggesting that selection for MDH1 amplification is not a driver or passenger aberration, rather may be selected for its ability to impart a proliferative advantage.
A hallmark of epithelial cancer cell behavior is the loss of contact inhibition, which can be measured by the ability to form non-adherent colonies in soft agar suspensions. We looked at soft agar colony formation following MDH1 overexpression in A549 lung cancer cells, which are highly glycolytic and particularly sensitive to lactate inhibition. 20, 23 Overexpression of MDH1 in A549 lung carcinoma cells resulted in significantly higher soft agar colony formation compared to lacZ-expressing controls (Figures 4d and e; Supplementary Figure 3c) . Furthermore, stable re-expression of MDH1-FLAG in Jurkat MDH1 KO cells increased their proliferation rate (Figure 4f ). Together, these data point to a significant role for MDH1 in supporting proliferation in human tumor cells, and underscore the potential for MDH1 inhibition as a therapeutic strategy.
Reductive carboxylation of glutamine supports MDH1 activity during proliferation The existing scenario designating LDH as the predominant source of cytosolic NAD regeneration presents two problems. First, the enhanced glycolysis associated with the proliferative state requires a one-to-one stoichiometry between glucose uptake and lactate production, not accounting for diversion of glucose carbons to biomass production. Second, the carbons that move through glycolysis to lactate are eventually secreted and lost, compounding the inefficiency. Evidence presented thus far points to MDH1 activity as a major alternative source of cytosolic NAD. Unlike lactate, which is largely disposed of as waste, malate can be further utilized for energy generation or for biomass. In addition, the possibility that MDH1 substrate, OAA, derives from a carbon source other than glucose must also be considered. We returned to our Noxa-overexpressing Jurkat cell model to test this possibility.
We used targeted metabolomics to trace the fate of carbons derived from [1,2- 13 C] D-glucose through glycolysis and into the TCA cycle (Figure 5a ). N5 cells showed increased enrichment of glycolytic metabolites through glyceraldehyde-3-phosphate (G3P), but not beyond phosphoglycerate (Figure 5b ). Glucose carbon enrichment in the pentose phosphate pathway intermediate S7P, indicated a fraction of glucose carbon was diverted to the pentose phosphate pathway (Supplementary Figures 4a and b) . Correspondingly, glucose contribution to TCA cycle intermediates was reduced in N5 cells (Figure 5c ). Importantly, enrichment of pyruvate and lactate in N5 cells was similar to controls (Figure 5b) , lending support to our previous observation that the increased glucose carbon consumed by N5 cells was diverted prior to enolase. 4 These data also argue for the existence of an alternative source other than lactate that regenerates NAD to support the increased glucose consumption we observe in these cells. 4 Glutamine serves as an alternative source of carbon for anaplerosis of the oxidative TCA cycle during proliferation. 24 Glutaminolysis produces alpha-ketoglutarate, which is metabolized to succinate following the release of CO 2 as it enters the TCA cycle (Figure 5a ). Targeted studies with uniformly labeled [U- 13 C] glutamine showed increased enrichment of glutamine carbons in the TCA cycle metabolites of N5 cells compared to controls (Figure 5d ). Glutamine contribution to lactate was, however, insignificant (Supplementary Figure 4c) .
Glutamine is also metabolized through reductive carboxylation where alpha-ketoglutarate is directly converted to isocitrate and citrate, which is then split into acetyl-CoA and oxaloacetate (OAA) in the cytosol 25 ( Figure 6a ). Although reductive carboxylation has been suggested as the preferred metabolic path for channeling glutamine carbons via acetyl-CoA into palmitate for de novo lipid synthesis 25, 26 (Figure 6a ), the fate of the cytosolic OAA has been less clear. We observed a significant increase in the enrichment of reductively generated citrate and acetyl-CoA (Figure 6b) , and MDH1-generated M3 malate, but not of M3 aspartate in the N5 cells (Figure 6c) . Overall, the pool abundance of metabolites generated from reductive metabolism of glutamine, including MDH1-generated malate, significantly increased in N5 cells (Figure 6d ). We had shown in Figure 1c that enrichment of M1 malate increased following co-stimulation of primary human T cells incubated with [4- 2 H] glucose. We also detected a significant increase in the reductive carboxylation of glutamine and production of M3 malate after stimulation both by enrichment percentage as well as pool abundance (Figures 6e and f) . Interestingly, despite the increase in percent enrichment of reductively generated aspartate, the M3 aspartate pool decreased after stimulation, suggesting that the generation of aspartate through the reductive pathway was independent of the proliferative state. Taken together, these data suggest that the increased MDH1 activity helps stem the flux of glucose carbons to LDHA by using glutamine as a carbon source to supply cytosolic NAD for glycolysis.
DISCUSSION
This study focuses on pathways proliferating cells utilize to provide GAPDH with a constant supply of its co-factor NAD to sustain accelerated glycolysis. The regeneration of cytosolic NAD from NADH has been largely attributed to the production of lactate through LDH activity. [1] [2] [3] However, a number of studies have reported that glucose carbons are lost to biosynthetic pathways, highlighting the need for a supplementary reaction and carbon source to regenerate cytosolic NAD. 3 This study shows that MDH1 plays a critical role in replenishing cytosolic NAD to support increased glycolysis during proliferation (Figure 6g) .
We initially identified MDH1 as a major source of cytosolic NAD using a strategy of labeling cells with [4- 2 H] glucose and tracing 13 C] glutamine following 24 h of labeling, detected using LC/MS. aKG, alpha-ketoglutarate; Fum, fumarate; Gln, glutamine; Glu, glutamate. Number of labeled carbons is indicated in parentheses. Data represented are the average and s.d. of triplicate samples from a representative experiment repeated at least twice. Significance was calculated using the Student's T-test (*Po 0.01, **P o0.001).
the deuterium from glucose into NADH, and then into [ 2 H]-labeled metabolites (Figure 1 ). The use of [4- 2 H] glucose to trace the utilization of NADH is a relatively novel strategy that has previously been used to investigate specific pathways. [27] [28] [29] Here we took an unbiased approach to identify novel sources of NAD regeneration during proliferation. This strategy revealed that malate is a significant hydrogen acceptor during proliferation not only in our Jurkat model but also in activated primary human T cells and in a variety of cancer cell lines, underscoring the physiological relevance of the pathway for replenishing the NAD supply in the cytosol. Moreover, MDH1 KO cells proliferate more slowly and consume less glucose compared to wild-type cells, whereas MDH1-overexpressing cells exhibit increased anchorage independence growth. This is the first study to reveal a strong association of MDH1 with proliferative metabolism and glycolysis.
These results do not contradict the numerous reports of increased lactate and LDH activity as a major supporter of the enhanced glycolysis in proliferating cells. Rather, the data suggest that malate synthesis likely serves as an alternative, and arguably more efficient, route for replenishing the NAD turning over rapidly in the cytosol. The efficiency arises from the fact that malate can be further metabolized for biomass, energy generation or ROS control, whereas lactate is primarily secreted into the extracellular environment as waste. A recent study has also demonstrated the importance of MDH1 activity in KRAS-driven pancreatic ductal carcinomas to control ROS by providing malate as a substrate for malic enzyme and NADPH production. 30 Moreover, LDHA inhibition did not significantly repress growth in Jurkat cells unless MDH1 was knocked out. Surprisingly, LDHA inhibition increased glucose consumption when MDH1 was present (Figure 2e ). We suggest that blocking the flow of carbons to LDHA in the presence of an active MDH1, capable of replenishing cytosolic NAD using glutamine carbons, increases the availability of glucose carbons for biomass. Thus, inhibition of LDHA could have a beneficial effect on these cells. Similar effects of inhibiting the downstream flow of glucose carbons have been described previously with a variant of pyruvate kinase (PKM2) expressed in proliferating cells. 31 We did not detect increased expression of MDH1 in N5 cells compared to JPar (Supplementary Figure 4D) . Additional cell culture models also seemed to express relatively similar levels of MDH1 (Supplementary Figure 4E) . However, The Cancer Genome Atlas database revealed MDH1 amplification in solid tumor models (Figure 4 ), suggesting that, unlike in cell culture models, the availability of substrate drives selection for MDH1 overexpression. A recent study also revealed MDH1 amplification and increased MDH1 activity in human PDAC samples. 30 In demonstrating the importance of MDH1-mediated malate synthesis to cytosolic NAD regeneration in highly glycolytic cells, this study offers fresh insights into metabolic alterations aimed at meeting the demands of growth and division and highlights the need for alternative strategies to target the increased consumption and utilization of glucose in cancers.
MATERIALS AND METHODS
Cell culture
Jurkat, HL60 and K562 (American Type Culture Collection, Manassas, VA, USA) cells were maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, 100 µg/ml streptomycin, NEAA and 4 mM L-glutamine. HEK293, A549 and HeLa (American Type Culture Collection) cells were maintained in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% FBS, 100 U/ml penicillin and 100 μg/ml streptomycin. JPar and N5 cells have been previously described. 4 MDH1 KO cells were a generous gift from Kivanc Birsoy and David Sabatini.
14 The LDHA inhibitor, GSK2837808A (Tocris Bioscience, Bristol, UK) was solubilized in dimethylsulphoxide, added to culture medium at the time of plating and maintained at 10 µM throughout the experiment. Concentration of glucose in the medium was measured via the EnzyChrom Glucose Assay kit (BioAssay Systems, Hayward, CA, USA) according to the manufacturer's protocol, and then normalized to cell counts. Concentration of lactate in the medium was measured via the Lactate Assay kit (Sigma-Aldrich, St Louis, MO, USA) following filtration through a 10 000 kDa MWCO spin filter. Lactate measurements were then normalized to cell number.
Plasmid constructs
The wild-type MDH1 vector was a kind gift from Hong-Duk Youn. 32 The MDH1 insert was amplified from the source vector to carry a 5′-FLAG tag and cloned into pcDNA 3.1 and verified by sequencing. The pcDNA 3.1 lacZ Myc/His construct was used as a vector control. Transfections were carried out in 5E6 and A549 cells using 1 µg of plasmid and 5 µl of FuGENE HD (Promega, Madison, WI, USA) reagent in 200 µl of antibiotic-free medium. After a 15-min incubation at ambient temperature, the DNA/FuGENE complex was added to a sub-confluent 10 cm plate containing 10 ml of antibiotic-free medium. After 24 h of transfection, medium was replaced and supplemented with 1 mg/ml of G418 (Geneticin, Invitrogen, Carlsbad, CA, USA) for 1 week. For Jurkat transfections, 10 µg of plasmid was electroporated using a Neon Transfection System (Invitrogen, Carlsbad, CA, USA) into 10E6 cells in a 100 µl Neon tip using 1350 V at a pulse width of 10 ms for three pulses. Cells were returned to antibiotic-free medium for 24 h. After 24 h, medium was supplemented with G418 for 10 days. Live cells were recovered using a Ficoll density gradient.
Western blot
Cells were washed 1 × with cold phosphate-buffered saline, resuspended in radio immunoprecipitation buffer supplemented with protease and phosphatase cocktails. Lysates were incubated on ice for 10 min and spun at 10 000 r.p.m. at 4°C in a microcentrifuge. The supernatant was collected for further analysis. Equal amounts of protein (10-50 μg) were resolved by SDS-polyacrylamide gel electrophoresis, transferred to nitrocellulose and probed with antibodies specific for Noxa (Santa Cruz, Santa Cruz, CA, USA; SC-56169), beta actin (Santa Cruz; SC-69879), MDH1 (Abcam, Cambridge, MA, USA; Ab180152), LDHA (Cell Signaling Technology, Danvers, MA, USA; #3582) or the FLAG epitope (SigmaAldrich; F7425).
Seahorse extracellular flux assay
Seahorse medium was supplemented with 10 mM glucose, 1 mM sodium pyruvate and 4 mM L-glutamine and adjusted to pH 7.4 with NaOH. Cells were plated at 250 000 cells per well and adhered to the Seahorse 96-well culture plate using CellTak (Corning, Oneonta, NY, USA). Extracellular acidification rate was measured using the Seahorse XFe96 (Agilent Technologies, Santa Clara, CA, USA).
Primary T-cell experiments
Human PBMCs were obtained from a healthy donor via Memorial Blood Center (St Paul, MN, USA). PBMCs were purified from red blood cells using Histopaque (Sigma-Aldrich). CD3+ T cells were isolated from PBMCs using the negative selection MACS magnetic separation system (Miltenyi Biotec, San Diego, CA, USA) and allowed to recover in RPMI-1640 supplemented with 10% FBS, 100 U/ml penicillin, 100 μg/ml streptomycin, NEAA and 4 mM L-glutamine overnight. At 18 h, live T cells were recovered by Ficoll density gradient centrifugation and allowed to rest for 4 h before being washed in glucose-free medium and starved of glucose for 1 h. For labeling, T cells were moved to culture dishes coated with 5 μg/ml anti-CD3 antibody (BioLegend, San Diego, CA, USA). An amount of 5 μg/ml of anti-CD-28 antibody (BioLegend) was then added along with 10 mM [4- Significance was calculated using the Student's T-test (*P o0.01, **P o0.001). (g) Simplified model to show how malate dehydrogenase 1 and glutamine help support the increased glucose uptake and glycolysis by replenishing the NAD consumed by the GAPDH catalyzed step, a function primarily attributed to LDH activity in highly glycolytic cells. Our studies suggest that, in proliferating cells, MDH1 is a significant alternative source of cytosolic NAD, utilizing the carbons from the reductive carboxylation of glutamine for the NADH-dependent synthesis of malate.
were washed and then resuspended in complete glutamine-free medium supplemented with 10% dialyzed FBS and 10 mM glucose for 3-4 h. Following depravation, 4 mM [U- 13 C] glutamine was added to the medium and cells were incubated for 24 h. Cells were then pelleted and washed 1 × in ice cold phosphate-buffered saline. Pellets were then resuspended in 100-200 μl − 20°C methanol, snap-frozen and stored at − 80°C. Liquid chromatography/mass spectrometry (LC/MS) and GC/MS were used for identification and quantification of labeled metabolites of all samples. [ Central carbon metabolism sample preparation Microtubes containing cell pellets were removed from − 80°C storage and maintained on wet ice throughout the processing steps. To initiate protein precipitation, 0.3 ml of a chilled mixture of methanol, chloroform and water (8:1:1; EMD, Billerica, MA, USA) was added to each sample, the mixture vortexed briefly and allowed to incubate on ice for 10 min. Post incubation, the vortex step was repeated, and samples centrifuged at 14 000 r.p.m., for 10 min in 4°C. Post centrifugation, 100 μl of supernatant was transferred to an autosampler vial for LC-MS analysis. From the remaining supernatant from each sample, a small aliquot was transferred to a new microtube to create a pooled sample for quality control purposes. The remaining supernatant from each sample was transferred to an autosampler vial, and brought to dryness. To each sample, 50 μl of 20 mg/ ml of a solution of methoxyamine hydrochloride in pyridine was added. Samples were vortexed briefly and the samples incubated at 37°C for 90 min. Samples were removed from heating and allowed to cool to room temperature. Addition of 50 μl of MTBSTFA with 1% tBDCMS (Regis Technologies, Morton Grove, IL, USA) and samples were incubated at 70°C for 1 h. Samples were allowed to cool and GC-MS was performed. A series of calibration standards were prepared along with samples for quality control of instrument performance and chromatography for both LC and GC analysis.
LC-MS analysis
LC-MS analysis was performed on an Agilent system consisting of a 1260 UPLC module coupled with a 6520 Quadrupole-Time-of-flight mass spectrometer (Agilent Technologies). Metabolites were separated on a 150 × 1 mm Luna NH 2 hydrophilic interaction chromatography column (Phenomenex, Torrance, CA, USA) using 10 mM ammonium acetate in water, adjusted to pH 9.9 with ammonium hydroxide, as mobile phase A, and acetonitrile, as mobile phase B. The flow rate was 0.075 ml/min and the gradient was linear 20-100% A over 15 min, followed by isocratic elution at 100% A for 5 min. The system was returned to starting conditions (20% A) in 0.1 min and held there for 10 min to allow for column re-equilibration before injecting another sample. The mass spectrometer was operated in Electrospray Ionization mode according to previously published conditions. 33 GC-MS analysis GC-MS analysis was performed on an Agilent 69890N GC-5975 MS detector with the following parameters: a 1 μl sample was injected splitlessly on an HP-5MS 15 m column (Agilent Technologies) with a helium gas flow rate of 1.4 ml/min. The GC oven initial temperature was 60°C and was increased at 10°C/min to 300°C, and held at 300°C for 5 min. The inlet temperature was 250°C and the MS source and quad temperatures were 230 and 150°C, respectively.
Metabolite data analysis
For LC-MS analysis, metabolite peaks (both molecular ion and stable isotopes) were identified by matching the retention time and mass (±10 p. p.m.) to authentic standards. For GC-MS, metabolite peaks (both molecular ion and stable isotopes) were identified by matching the retention time and mass (±0.2 Da) to authentic standards. Metabolite masses (M-H for LC-MS, TBDMS derivative for GC-MS) are indicated in Supplementary  Table 1 , along with the qualifying ions used for the GC-MS identification. Isotope peaks (natural abundance and stable isotope labeling) were identified as increments of +1.0034 and +1 Da, respectively, for LC-and GC-MS, from the masses shown in the Supplementary Table 1. Presence of stable isotope labeling above the natural abundance was verified by absence of the same MS peak in the unlabeled preparation of the same condition. Peak areas were integrated using MassHunter Quantitative Analysis vB.07.00 (Agilent Technologies). Peak areas were corrected for natural isotope abundance (using an in-house written software package based on the method described previously) 28 and the residual isotope signal was reported. Data were normalized to cell protein content prior to analysis of metabolite fluxes for Central Carbon metabolites.
Soft agar colony assays oft agar plates were prepared by mixing 3.2% low melt agarose with DMEM culture medium to yield 0.8% agarose at 38.5°C. A volume of 1 ml was added per well of a six-well plate and allowed to solidify. A total of 11 500 cells per ml were then mixed with 3.2% agarose to yield 0.48% agarose in DMEM culture medium and allowed to solidify. A volume of 1 ml of DMEM supplemented with 1 mg/ml G418 was added to the top of the agarose. Each condition was plated in triplicate. Plates were incubated for 15 days. Colonies were stained with 0.005% crystal violet in phosphatebuffered saline and 4% formaldehyde. Images were captured on an inverted microscope using QCapture software (Surrey, BC, Canada). Ten microscopic fields were captured and counted per condition. Colonies were counted using ImageJ software (National Institutes of Health, Bethesda, MD, USA).
